- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
IL-6 Inhibitors May Reduce the Risk and Progression of Diabetic Retinopathy: Study

Diabetic patients receiving interleukin-6 (IL-6) inhibitors for other medical conditions had a significantly lower risk of developing diabetic retinopathy (DR) when compared to matched controls, according to a study published in the journal of Ophthalmology. The treatment was also associated with reduced risk of DR progression and the need for ophthalmic interventions.
Systemic interleukin-6 (IL-6) inhibitors may offer a potential protective association against diabetic eye disease, according to findings from study using data from the US TriNetX healthcare network. Thus, this study evaluated whether IL-6 pathway inhibition was associated with reduced incidence and progression of diabetic retinopathy, as well as fewer sight-threatening complications and retinal interventions.
This study identified adults with type 1 or type 2 diabetes between January 1, 2004, and May 30, 2026. Following 1:1 propensity score matching, the primary analysis included 2,605 patients receiving systemic IL-6 inhibitors and 2,605 matched controls. A secondary analysis examined 1,057 matched patients in each group with pre-existing nonproliferative diabetic retinopathy (NPDR).
The study assessed the risks of developing NPDR and proliferative diabetic retinopathy (PDR), along with complications including diabetic macular edema (DME), vitreous hemorrhage (VH), and neovascular glaucoma (NVG). The need for anti-vascular endothelial growth factor (anti-VEGF) injections, panretinal photocoagulation (PRP), and pars plana vitrectomy (PPV) was also evaluated over one-, three-, and five-year follow-up periods.
IL-6 inhibitor use was associated with approximately 50% lower 5-year risk of developing NPDR and 53% lower risk of PDR when compared to matched controls. The association extended to other vision-threatening complications, with a 63% lower risk of DME and a 59% lower risk of vitreous hemorrhage. No statistically significant difference was observed for neovascular glaucoma.
Patients receiving IL-6 inhibitors also had significantly lower 5-year rates of retinal interventions, including anti-VEGF therapy, PRP, and PPV, which suggests a potential reduction in the clinical burden of advanced diabetic eye disease.
Among patients with established NPDR, IL-6 inhibitor use was similarly associated with lower risks of progression to PDR, DME, VH, NVG, and the need for retinal interventions. Importantly, the findings remained consistent in active comparator analyses involving alternative immunosuppressive treatments.
These findings highlight the potential importance of inflammatory pathways in diabetic retinal disease. Overall, IL-6 inhibition may represent a promising therapeutic pathway for preventing and slowing diabetic retinopathy, which highlighted the potential role of inflammation in its pathogenesis. Further prospective clinical trials are needed to establish efficacy and safety.
Source:
Abdi, A., Alshaikhsalama, A., Zaidi, Z., Alsoudi, A. F., Yuan, M., Faia, L. J., Mruthyunjaya, P., & Rahimy, E. (2026). Systemic interleukin-6 inhibition and risk of diabetic retinopathy development and progression. Ophthalmology. https://doi.org/10.1016/j.ophtha.2026.07.029
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

